About Acorda
Acorda is a company based in Ardsley (United States) founded in 1995 was acquired by Merz in May 2024.. Acorda has raised $66.5 million across 3 funding rounds from investors including J P Morgan, ABN AMRO and Easton Capital Investment Group. The company has 109 employees as of December 31, 2022. Acorda has completed 3 acquisitions, including Biotie, Civitas Therapeutics and Neuronex. Acorda offers products and services including AMPYRA, INBRIJA, and ARCUS Technology. Acorda operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Ardsley, United States
- Employees 109 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Acorda Therapeutics Inc.
-
Annual Revenue
$118.57 M-8as on Dec 31, 2022
-
Net Profit
$-65.92 M37as on Dec 31, 2022
-
EBITDA
$-35.34 M55as on Dec 31, 2022
-
Total Equity Funding
$66.5 M (USD)
in 3 rounds
-
Latest Funding Round
$31.5 M (USD), Post-IPO
Oct 01, 2006
-
Investors
J P Morgan
& 4 more
-
Employee Count
109
as on Dec 31, 2022
-
Investments & Acquisitions
Biotie
& 2 more
-
Acquired by
Merz
(May 15, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Acorda
Acorda offers a comprehensive portfolio of products and services, including AMPYRA, INBRIJA, and ARCUS Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug for improving walking in multiple sclerosis patients.
Inhalation powder for managing Parkinson's disease symptoms.
Technology platform for neurological drug delivery systems.
Unlock access to complete
Unlock access to complete
Funding Insights of Acorda
Acorda has successfully raised a total of $66.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $31.5 million completed in October 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $31.5M
-
First Round
First Round
(09 May 2003)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2006 | Amount | Post-IPO - Acorda | Valuation |
investors |
|
| Mar, 2004 | Amount | Series C - Acorda | Valuation |
investors |
|
| May, 2003 | Amount | Series C - Acorda | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Acorda
Acorda has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, ABN AMRO and Easton Capital Investment Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Capital is invested in life science innovations for healthcare transformation.
|
Founded Year | Domain | Location | |
|
ABN AMRO is recognized as a personal bank in the digital era.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Acorda
Acorda has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Biotie, Civitas Therapeutics and Neuronex. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Nasal spray formulation of diazepam is developed for seizure disorders.
|
2010 | ||||
|
Inhaled pulmonary therapies for Parkinson's motor fluctuations are developed.
|
2009 | ||||
|
Drugs for neurodegenerative and psychiatric disorders are developed by Biotie.
|
1998 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Acorda
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Acorda Comparisons
Competitors of Acorda
Acorda operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Acorda
Frequently Asked Questions about Acorda
When was Acorda founded?
Acorda was founded in 1995 and raised its 1st funding round 8 years after it was founded.
Where is Acorda located?
Acorda is headquartered in Ardsley, United States. It is registered at Ardsley, New York, United States.
Is Acorda a funded company?
Acorda is a funded company, having raised a total of $66.5M across 3 funding rounds to date. The company's 1st funding round was a Series C of $55M, raised on May 09, 2003.
How many employees does Acorda have?
As of Dec 31, 2022, the latest employee count at Acorda is 109.
What is the annual revenue of Acorda?
Annual revenue of Acorda is $118.57M as on Dec 31, 2022.
What does Acorda do?
Acorda Therapeutics was founded in 1995 as a biopharmaceutical company focused on the identification, development, and commercialization of treatments for neurological conditions, including multiple sclerosis and spinal cord injury. Operations center on products such as Ampyra, approved in 2010 for improving walking in MS patients, and Zanaflex Capsules for spasticity management. The company is headquartered in Ardsley, United States, within the healthcare sector.
Who are the top competitors of Acorda?
Acorda's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
What products or services does Acorda offer?
Acorda offers AMPYRA, INBRIJA, and ARCUS Technology.
How many acquisitions has Acorda made?
Acorda has made 3 acquisitions, including Biotie, Civitas Therapeutics, and Neuronex.
Who are Acorda's investors?
Acorda has 5 investors. Key investors include J P Morgan, ABN AMRO, Easton Capital Investment Group, TVM Capital Life Science, and Merz Therapeutics.